Skip to content
Business websites
Business websites
J&J Innovative Medicine
J&J MedTech
J&J Innovative Medicine
J&J MedTech
Location
Language
English
Choose your country or region
China
中国人
France
Français
India
English
Japan
日本
Switzerland
Deutsch
English
Français
US
English
UK
English
Latest news
Innovation
Caring & giving
Personal stories
Health & wellness
Our Company
Discover J&J
Our Credo
Our Leadership
Code of Business Conduct
Corporate reports
Diversity, Equity & Inclusion
ESG Policies & Positions
Innovation at J&J
Uniting science and technology
Office of the Chief Medical Officer
Veterans, military & military families
Innovative Medicine
MedTech
Our societal impact
Global Health Equity
Global environmental sustainability
Suppliers
Responsible supply base
Supplier-enabled innovation
Supplier resources
Our heritage
Careers
Search jobs
Life at J&J
Employee benefits
Professional development
Employee stories
Our teams
Oncology
Immunology
Data science
Market access
Medical affairs
Innovation, development and partnerships
MedTech and surgical robotics
Locations
North America
EMEA
Asia Pacific
Latin America
Student opportunities
Internships
Co-ops
Full-time student jobs
Leadership and development opportunities
How we hire
Application tips
Hiring programs
Hiring FAQs
Join our Global Talent Hub
Investors
Pharmaceutical pipeline
ESG resources
Investor fact sheet
Media Center
Press releases
Menu
Latest news
Innovation
Caring & giving
Personal stories
Health & wellness
Our Company
Discover J&J
Our Credo
Our Leadership
Code of Business Conduct
Corporate reports
Diversity, Equity & Inclusion
ESG Policies & Positions
Innovation at J&J
Uniting science and technology
Office of the Chief Medical Officer
Veterans, military & military families
Innovative Medicine
MedTech
Our societal impact
Global Health Equity
Global environmental sustainability
Suppliers
Responsible supply base
Supplier-enabled innovation
Supplier resources
Our heritage
Careers
Search jobs
Life at J&J
Employee benefits
Professional development
Employee stories
Our teams
Oncology
Immunology
Data science
Market access
Medical affairs
Innovation, development and partnerships
MedTech and surgical robotics
Locations
North America
EMEA
Asia Pacific
Latin America
Student opportunities
Internships
Co-ops
Full-time student jobs
Leadership and development opportunities
How we hire
Application tips
Hiring programs
Hiring FAQs
Join our Global Talent Hub
Investors
Pharmaceutical pipeline
ESG resources
Investor fact sheet
Media Center
Press releases
Search Query
Submit Search
Clear
Dictate search request
Search Results
No Results
Recently Viewed
Listening...
Sorry, I don't understand. Please try again
Show Search
Home
/
Media Center
/
Press releases
Press releases
Press Releases
Search Query
Submit Search
Clear
Dictate search request
Listening...
Sorry, I don't understand. Please try again
2,106 Results
Date
All Dates (2106)
Past 30 days (18)
2023 (140)
2022 (124)
2021 (185)
2020 (110)
2019 (130)
2018 (166)
2017 (194)
2016 (125)
Topic
All (2106)
Corporate (144)
Financial (301)
Global Health Equity (59)
Innovative Medicine (959)
Leadership (20)
Medical technologies (289)
Research (41)
2,106 results
Filters
Date
All Dates (2106)
Past 30 days (18)
2023 (140)
2022 (124)
2021 (185)
2020 (110)
2019 (130)
2018 (166)
2017 (194)
2016 (125)
Topic
All (2106)
Corporate (144)
Financial (301)
Global Health Equity (59)
Innovative Medicine (959)
Leadership (20)
Medical technologies (289)
Research (41)
Sort By:
Newest
Newest
Relevance
Oldest
March 27, 2025
Johnson & Johnson MedTech to Highlight Latest Advancements in Heart Disease Treatment with Impella at ACC.25
Impella heart pump upgraded to Class 2a in ACC/AHA treatment guideline for cardiogenic shock secondary to STEMI
Read more
March 26, 2025
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) outperforms osimertinib with a significant and unprecedented overall survival benefit in patients with EGFR-mutated non-small cell lung cancer
Median overall survival not yet reached with projected improvement of more than one year versus osimertinib
Read more
March 26, 2025
New nipocalimab data and real-world research at AAN 2025 highlight positive Phase 3 results and commitment to people living with generalized myasthenia gravis (gMG)
Oral presentation features new data from the 24-week pivotal Vivacity-MG3 study which show sustained disease control through treatment with nipocalimab on the clinician-assessed QMGa score in antibody positive adult patients: anti-AChR+, anti-MuSK+, anti-LRP4+ Nipocalimab data demonstrate longer-term sustained disease control as measured by MG-ADLb and QMG scores from the ongoing open-label extension (OLE) of the Vivacity-MG3 study Johnson & Johnson filed a Biologics License Application (BLA) for nipocalimab in August 2024 and was granted U.S. FDA Priority Review for the treatment of gMG Real-world studies highlight the unmet need of patients living with gMG, including those who are pregnant or receiving steroids
Read more
March 25, 2025
Johnson & Johnson MedTech Launches the DUALTO™ Energy System for Use Across Surgical Treatment Approaches
The DUALTO™ electrosurgical generator is designed to offer a simplified user experience, access to Polyphonic™ Fleet digital device management, and flexible application of monopolar, bipolar, ultrasonic, and advanced bipolar energy devices for open and minimally invasive surgery DUALTO will be showcased at the Association of periOperative Registered Nurses Global Surgical Conference & Expo on April 5-8, 2025 The DUALTO Energy System recently received 510(k) clearance by the U.S. Food & Drug Administration1
Read more
March 21, 2025
Johnson & Johnson Increases U.S. Investment to More than $55 Billion Over the Next Four Years
Investment builds on almost 140-year legacy of improving and saving lives and supporting American jobs Includes four planned new manufacturing facilities, with ground-breaking today in North Carolina on $2 billion+ facility Total Company U.S. economic impact estimated to be more than $100 billion per year
Read more
March 21, 2025
Johnson & Johnson to break ground on new state-of-the-art biologics facility in North Carolina to deliver market-leading portfolio of transformational therapies
•New facility will support plans to advance J&J’s portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases •Delivering on Company’s plans for increased U.S. investment, $2 billion+ advanced biologics facility will add more than 5,000 high-wage manufacturing and construction jobs in North Carolina. •Investment will create an estimated economic impact of $3 billion statewide during first 10 years of site operation
Read more
March 20, 2025
U.S. FDA approves TREMFYA® (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn’s disease
TREMFYA® is the only IL-23i to demonstrate clinical remission and endoscopic response, both at one year, with a fully subcutaneous induction regimen Supported by data from the GALAXI study, TREMFYA® is the only IL-23i to show superiority versus STELARA® in all pooled endoscopic endpoints within a double-blinded registrational trial TREMFYA® approval in Crohn’s disease builds upon recent ulcerative colitis FDA approval, marking the fourth indication for this dual-acting IL-23i in the U.S.
Read more
Innovative Medicine
March 20, 2025
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) significantly outperforms standard of care in first-line EGFR-mutated lung cancer with compelling new data at ELCC 2025
Median overall survival improvement projected to exceed one year with much-anticipated overall survival analysis showing statistically superior result versus osimertinib Preventative dermatologic regimen meets primary endpoint and enhances patient experience
Read more
Innovative Medicine
March 18, 2025
Nipocalimab, the first and only investigational treatment to be granted U.S. FDA Breakthrough Therapy designation for the treatment of adults with moderate-to-severe Sjögren’s disease, has now received Fast Track designation
Sjögren’s disease (SjD) is a prevalent, debilitating autoantibody disease with no FDA-approved advanced treatments The Company is actively enrolling patients in the Phase 3 DAFFODIL study This marks the fourth nipocalimab FDA Fast Track designation
Read more
Medical technologies
March 12, 2025
Johnson & Johnson MedTech Announces Clearance of MONARCHTM QUEST for Enhanced Robotic-Assisted Bronchoscopy
Next-generation NVIDIA-powered AI navigation software elevates MONARCHTM Platform for Robotically Assisted Bronchoscopy
Read more
Load More